Skip to main content
. 2011 Dec;96(12):1846–1854. doi: 10.3324/haematol.2011.047696

Figure 1.

Figure 1.

Outcome. (A) Cumulative percentage of overall survival (OS), non-relapse mortality (NRM), and relapse mortality (REL) in months following allogeneic HSCT; OS, NRM and REL (which are competing risks) sum up to 100% at all time points. (B) Cumulative percentage of OS stratified by EBMT risk score in months following allogeneic HSCT (log rank: P=0.01).